Harte Hanks heads into its May 14 earnings report with short interest at its highest level in months and the stock trading nearly 40% below where it was a year ago.
The most striking development in the positioning data is the pace of short rebuilding. Short Interest % of Free Float has nearly doubled since mid-April, jumping from around 0.98% on April 10 to 1.71% by April 28. That move — a 70% rise in estimated short shares over the past month — is large in relative terms for a name this thinly traded, and it reverses what had been a gentle drift lower through March. The step-change came on April 14, when SI % FF leapt from below 1% to 1.56% in a single session, coinciding with the company appearing in pre- and after-market mover screens. It has not come back down since.
The borrow market tells a calmer story. Cost to borrow is running at roughly 2%, modest for a micro-cap and actually down about 9% on the week — the lending pool is not under stress. Availability remains loose, with just 6.6% of lendable shares currently out on loan against a 52-week peak of 15%. Shorts are adding positions, but the borrow infrastructure around that move is relaxed rather than strained. The ORTEX short score of 40.4 lands in the mid-range — elevated relative to early April readings in the high 30s, but nowhere near the danger zone.
What the shorts are responding to is a stock that has struggled badly. HHS closed April 28 at $2.75, down 0.7% on the week. The stock is up 16% over the past month from lower levels, but remains deeply depressed. The ownership structure is concentrated and largely passive: Gary Rosenbach holds nearly 29% of shares, the Harte estate holds another 9%, and William Blair and Westerly Capital each hold around 8-9%. Together, the top four holders control over 55% of shares outstanding. That concentration limits liquidity and amplifies any move in either direction when trading volumes are as thin as they have been.
Analyst coverage is absent in any practical sense — the most recent price target on record dates back to August 2024, making it too stale to carry weight in this note. Valuation is opaque at this size: the company's enterprise value is estimated at roughly $35 million, consistent with a business under real revenue pressure in a sector where AI tools are disrupting traditional direct marketing. The stock's last two earnings releases both generated negative day-one reactions of around 3-5% and five-day slides of roughly 11%.
That earnings history gives context to the short rebuilding. The May 14 print is the next event worth watching — specifically whether the five-day reaction pattern holds, and whether the recent short build reflects informed repositioning ahead of results or simply noise in a thinly-traded name.
See the live data behind this article on ORTEX.
Open HHS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
